SEC Form 4 · accession 0001237899-16-000089
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Powchik
Officer — SVP Clinical Development & Reg
Period of report
Dec 16, 2016
Accepted (ET)
Dec 19, 2016 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 16, 2016 | G | 2,459 | $0.00 | D | 2,459 | I | by GRAT |
| Common Stock | May 16, 2016 | G | 2,459 | $0.00 | D | 0 | I | by GRAT |
| Common StockF1 | May 16, 2016 | G | 2,459 | $0.00 | A | 2,459 | I | by Trust for Son |
| Common StockF2 | May 16, 2016 | G | 2,459 | $0.00 | A | 2,459 | I | by trust for daughte |
| Common Stock | holding | — | — | — | 25,714 | D | ||
| Common Stock | holding | — | — | — | 1,674 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $381.92 | Dec 16, 2016 | A | 5,000 | A | — | Dec 16, 2026 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1By a trust for the benefit of the reporting person's son of which the reporting person's spouse is trustee.
- F2By a trust for the benefit of the reporting person's daughter of which the reporting person's spouse is trustee.
- F3The stock option award vests in full one year after the date of grant.